VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
In this Healio Video Perspective from the ASRS meeting, Diana V. Do, MD, FASRS, of Byers Eye Institute discusses data from the PHOTON trial investigating aflibercept 8 mg and aflibercept 2 mg for the treatment of diabetic macular edema.
Patients were divided into two groups, with a baseline visual acuity of 20/50 or worse or 20/40 or better, to evaluate visual acuity and anatomic outcomes after treatment with both doses of aflibercept.
“The key findings from our research showed that, regardless of baseline visual acuity, both aflibercept 8 mg or aflibercept 2 mg were very effective and comparable in improving visual acuity and reducing retinal thickness,” Do said.
Collapse
Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about